Clinical trial
Comparative Antiresorptive Efficacy of Alendronate or Raloxifene Following Discontinuation of Denosumab
NCT03623633 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Comparative Antiresorptive Efficacy of Alendronate or Raloxifene Following Discontinuation of Denosumab
- Lead sponsor
- Massachusetts General Hospital
- Phase
- Phase 4
- Overall status
- Active, not recruiting
- Start date
- November 30, 2018
- Completion date
- August 1, 2023
- Enrollment
- 51 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.